| Similar Articles |
|---|
 |
National Real Estate Investor
October 31, 2003
Parke Chapman |
Starwood CEO Barry Sternlicht To Resign Barry Sternlicht, CEO of global hotel owner Starwood Hotels & Resorts, is stepping down after running the firm for eight years. Sternlicht's resignation will not become effective until a successor is found, at which point Sternlicht will become executive chairman.   |
National Real Estate Investor
January 31, 2003
Parke Chapman |
Starwood reports 12% revenue increase for '02 Although its near-term forecast is clouded by the United States' potential conflict with Iraq, Starwood Hotels & Resorts Worldwide Inc. has reported a 12% revenue increase for the fourth quarter of 2002. |
National Real Estate Investor
February 9, 2004
Parke Chapman |
Starwood Beats Wall Street Estimates Despite a 4.4% decline in profits, Starwood Hotels & Resorts Worldwide beat Wall Street estimates for the fourth quarter of 2003. |
BusinessWeek
November 24, 2003
Robert Barker |
Is Starwood Losing Star Power? With its star CEO Barry Sternlicht semi-retiring at age 42, hotelier Starwood may be setting out on a course destined to yield a host of new, unseen risks. |
The Motley Fool
October 27, 2004
W.D. Crotty |
Gallagher's Mixed Bag The insurance brokerage reports good earnings, but a subpoena sinks its stock. |
The Motley Fool
January 27, 2004
Jeff Hwang |
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. |
The Motley Fool
July 10, 2007
Selena Maranjian |
Hotels in the News That Holiday Inn down the street from your office might have been around for 30 years, but don't assume the entire hotel industry is equally sleepy. Investors and guests alike might be intrigued by these recent developments. |
The Motley Fool
November 12, 2010
Sean Williams |
Starwood Hotels: Bargain or Value Trap? High-end consumers are spending, but debt levels look dangerous. |
The Motley Fool
January 23, 2006
Rich Duprey |
Luxury Lodging Lights Up Hilton will be branding the Waldorf name while a former Starwood exec looks for opulence. It's a smart move by the hoteliers. Investors, take note. |
The Motley Fool
June 23, 2005
Stephen D. Simpson |
Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist? |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
October 20, 2004
Rogene Calvet |
Is Marsh Ringing the Value Bell? Does a troubled global insurer offer a buying opportunity? |
The Motley Fool
October 18, 2004
Bill Mann |
Marsh's 2nd Annual Massive Fraud? Marsh & McLennan has been cut in half in the last three days following allegations that it had rigged bids to convince its customers to overpay for insurance policies that it brokered on their behalf. |
The Motley Fool
September 17, 2008
Rick Aristotle Munarriz |
Throw This Stock Away There are plenty of reasons these days to avoid the hospitality sector altogether, and Starwood in particular. |
The Motley Fool
June 23, 2005
Stephen D. Simpson |
Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects. |
The Motley Fool
December 3, 2004
Philip Durell |
Hunting for Value: Part 2 This value investor looks for Fallen Angels, Bankruptcy Survivors and the elusive Stealth Stocks. |
BusinessWeek
November 1, 2004
Marcia Vickers |
The Secret World of Marsh Mac CEO Jeff Greenberg presides over the arrogant and tight-lipped culture of Marsh & McLennan, where conflicts of interest abound. There's more trouble coming from Eliot Spitzer for the world's largest insurance broker. |
Pharmaceutical Executive
January 1, 2006
Jeannette Park |
Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future. |
BusinessWeek
May 31, 2004
Diane Brady |
Marsh Mac's Integrity Injection The beleaguered financial-services giant places a bet on premier risk consultancy Kroll Inc. |
The Motley Fool
February 3, 2005
Nathan Slaughter |
Starwood's a Star The hotel operator rides strong business and international travel for strong fourth quarter results. |
The Motley Fool
October 27, 2004
Bill Mann |
When in Doubt, Decapitate Eliot Spitzer announced that the State of New York would not pursue criminal charges against disgraced insurance broker Marsh & McLennan after it promised reforms and accepted the resignation of its CEO, replacing him with a former Manhattan prosecutor. |
The Motley Fool
February 14, 2011
Zeeshan Siddique |
A Quiet Resurgence of the American Hotel Industry Is this the beginning of something new? |
The Motley Fool
January 14, 2011
Brian Orelli |
Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing. |
The Motley Fool
October 15, 2004
Bill Mann |
No Better Than Two-Bit Hustlers Marsh & McLennan's expertise apparently included convincing clients to overpay for insurance. |
The Motley Fool
August 7, 2007
Ryan Fuhrmann |
A Mixed Quarter at Marsh Marsh Mac's current sluggish growth may soon speed up. The financial-services firm doesn't expect improved profitability until at least the end of this year, but the sale last week of the struggling Putnam Investments division is a good step in that direction. |
The Motley Fool
May 5, 2010
Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
The Motley Fool
November 15, 2005
Nathan Slaughter |
Starwood Makes Room The hotel chain sells 38 properties to Host Marriott for $4 billion in cash and stock. While there is some near-term uncertainty for Host shareholders as Starwood owners decide whether to keep or unload their new shares, the outlook for Starwood appears brighter than ever. |
BusinessWeek
April 23, 2007
Alex Halperin |
Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review. |
The Motley Fool
December 8, 2004
Rich Smith |
Spitzer for Governor? Crusading prosecutor takes aim at New York's governor's mansion. |
The Motley Fool
December 21, 2006
Ryan Fuhrmann |
Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space. |
The Motley Fool
October 4, 2004
Mathew Emmert |
Got Merck? The pharmaceutical's investors can't seem to catch a break. |
The Motley Fool
October 26, 2004
Rich Duprey |
Aon Mired in Marsh World's second-largest insurance broker accused of improper business practices. |
The Motley Fool
July 27, 2005
Nathan Slaughter |
No Applause for Starwood The hotelier posts excellent second quarter results, but investors aren't impressed. |
